High doses of MYP treatment improved depression, pain, and fatigue behaviors in reserpine-induced mice, and these therapeutic effects were associated with the regulation of c-Fos, 5-HT1A/B receptors, and TGF-β1 expression in the brain. This evidence concerns the gene FOS and major depressive disorder.